Patent ID: 8648083

Claim:
A method of treating, diabetic hyperlipidemia, or hyperlipidemia, comprising administering a therapeutically effective amount of a compound selected from the group consisting of: carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-3-oxo-1-phenyl-propyl ester; carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-1-(4-fluoro-phenyl)-3-oxo-propyl ester; carbamic acid 3-(4-benzo[1,3]dioxol-5-yl-piperazine-1-yl)-3-oxo-1-phenyl-propyl ester; carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-1-(4-trifluoromethyl-phenyl)-3-oxo-propyl ester; carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-1-(4-nitro-phenyl)-3-oxo-propyl ester; (R)-carbamic acid 3-[4-(4-chloro-phenyl)-piperazine-1-yl]-3-oxo-1-phenyl-propyl ester; (S)-carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-3-oxo-1-phenyl-propyl ester; (R)-carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-3-oxo-1-phenyl-propyl ester; carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-1-phenyl-butyl ester; and carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazine-1-yl]-1-(4-chloro-phenyl)-3-oxo-propyl ester, or a pharmaceutically acceptable salt, isomer, solvate, or hydrate thereof, to a subject in need of treatment.